Tracks outcomes of people with relapsed myeloma treated with teclistamab or talquetamab
Describes use of teclistamab or talquetamab in adults with relapsed myeloma outside trials.
Plain-language title generated from the registry record
Registry title: A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials
Key facts
- Where
- Cork, Dublin, and Galway, IrelandSee the 5 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with multiple myeloma who have already been treated with teclistamab or talquetamab outside of a clinical trial.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- A documented diagnosis of multiple myeloma.
- Earlier treatment
- Must have received at least one dose of teclistamab or talquetamab. The first dose must fall within the dates set for the cohort. Treatment given as part of an interventional clinical trial does not count.
Main reasons for not taking part
- Received teclistamab as part of an interventional clinical trial (REALiTEC cohorts)
- Received talquetamab as part of an interventional clinical trial (REALiTAL cohort)
- Received teclistamab through a Janssen pre-approval access program (REALiTEC Cohort 2 and Cohort 3)
Read by machine on 12 November 2026.
Where in Ireland
- Bon Secours HospitalCork, IrelandNo longer taking part
- Cork University HospitalCork, IrelandNo longer taking part
- Beacon HospitalDublin, IrelandNo longer taking part
- St James HospitalDublin, IrelandNo longer taking part
- University Hospital Galway - IrelandGalway, IrelandNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Janssen-Cilag Ltd.
- Trial code
- NCT06285318
- Record updated
- 28 August 2026
- Original description
The purpose of this study is to describe the use of teclistamab/talquetamab in the treatment of patients with RRMM outside of clinical trials.Read full original descriptionShow less
64007957MMY4004: 64007957MMY4004 - REALiTEC
The purpose of this study is to describe the use of teclistamab/talquetamab in the treatment of patients with RRMM outside of clinical trials.
Inclusion: Have a documented diagnosis of multiple myeloma; Received the first dose of teclistamab on or before 31 December 2022, regardless of the duration of teclistamab treatment (REALiTEC cohort 1) OR Received the first dose of teclistamab from 01 January 2023 to 31 December 2024, inclusive, regardless of the duration of teclistamab treatment (REALiTEC cohort 2) OR Received the first dose of teclistamab from 01 January 2025 to 31 December 2025, inclusive, regardless of the duration of teclistamab treatment (REALiTEC cohort 3) OR Received the first dose of talquetamab on or before 31 December 2023, regardless of the duration of talquetamab treatment (REALiTAL cohort). Participants who received both teclistamab \& talquetamab can be included in both REALiTEC and REALiTAL cohorts; Received at least one dose of teclistamab/talquetamab; Provision of a patient-signed informed consent form (ICF), or an ICF waiver for deceased patients as applicable based on country/site-specific requirements.
Exclusion: To be excluded from REALiTEC cohorts if received teclistamab as part of an interventional clinical trial; To be excluded from REALiTAL cohort if received talquetamab as part of an interventional clinical trial; Participants who have received teclistamab as part of a Janssen pre-approval access program are excluded from the REALiTEC Cohort 2 and REALiTEC Cohort 3.